DiaMedica Therapeutics Inc — Cash Flow (NASDAQ:DMAC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities -9.19 M-12.25 M-11.51 M-18.73 M-22.08 M -27.73 M Cash from investing activities -16.13 M-20.54 M11.54 M-18.3 M8.56 M -4.98 M Cash from financing activities 28.84 M30.09 M-6 00036.84 M11.99 M 31.91 M Free cash flow -9.23 M-12.27 M-11.59 M-18.75 M-22.1 M -27.77 M

News

Cantor Fitzgerald reiterates Overweight rating on DiaMedica stock

DiaMedica to conduct additional study for preeclampsia treatment

Cisco, Flutter, Manulife and more set to report earnings Wednesday

DiaMedica Therapeutics stock initiated with Buy rating at TD Cowen

Tracking Leon Cooperman’s ~$3B Omega Advisors Portfolio – Q2 2025 Update

DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?

After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright

Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade

What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?

Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?

DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia (NASDAQ:DMAC)

DiaMedica therapeutics (DMAC): Trill AB buys $5.4m in shares